B-ALL was determined to be high-risk based on negative prognostic markers (e.g., deletion of one IKZF1 allele, CRLF2 overexpression etc.)and/or clinical features (Table S1). This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.